Escobar M, Luck J, Averianov Y, Ducore J, Fernández MFL, Giermasz A, et al. PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia. 2021;27(6):911-20.
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors
By Content Specialist|2022-06-14T22:05:34+02:00June 14, 2022|2021 Publication, 2021: October to December|Comments Off on PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors
Share This Story, Choose Your Platform!
About the Author: Content Specialist
Related Posts
In Utero Human Cytomegalovirus Infection Is Associated With Increased Levels of Putatively Protective Maternal Antibodies in Nonprimary Infection: Evidence for Boosting but Not Protection